SCHEMBL134043

SCHEMBL134043

Oc1cc(Cl)c(O)c(O)c1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 12/20 0.50
TSHR P16473 10/20 0.50
HPGD P15428 8/20 0.50
CYP3A4 P08684 6/20 0.50
ALDH1A1 P00352 4/20 0.50
TTR P02766 3/20 0.50
RECQL P46063 3/20 0.50
THRB P10828 3/20 0.46
MAPK1 P28482 3/20 0.46
HSP90AA1 P07900 2/20 0.46
ALOX15 P16050 3/20 0.43
ALOX12 P18054 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
HIF1A Q16665 3/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2C19 P33261 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
CYP2C9 P11712 1/20 0.43
CASP1 P29466 2/20 0.43
MEN1 O00255 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11234833 0.79 HSD17B10 (0.57) HSD17B10TSHRHPGDCYP3A4ALDH1A1
SCHEMBL11879785 0.79 HSD17B10 (0.57) HSD17B10TSHRHPGDCYP3A4ALDH1A1
SCHEMBL9099561 0.79 HSD17B10 (0.63) HSD17B10TSHRHPGDCYP3A4ALDH1A1
SCHEMBL1961108 0.75 SELL (0.47) HSD17B10HPGDCYP3A4ALDH1A1TTR
SCHEMBL4450834 0.75 HSD17B10 (0.43) HSD17B10TSHRHPGDCYP3A4ALDH1A1
SCHEMBL69390 0.73 HSD17B10 (0.65) HSD17B10TSHRHPGDCYP3A4ALDH1A1
SCHEMBL70606 0.73 HSD17B10 (0.65) HSD17B10TSHRHPGDCYP3A4ALDH1A1
SCHEMBL70194 0.73 HSD17B10 (0.72) HSD17B10TSHRHPGDCYP3A4ALDH1A1
SCHEMBL12804729 0.73 HSD17B10 (0.55) HSD17B10TSHRHPGDCYP3A4ALDH1A1
SCHEMBL70334 0.72 HSD17B10 (0.73) HSD17B10TSHRHPGDCYP3A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4370158-A1 PORPHYRIN NANOVESICLE WITH FATTY ACID CONJUGATE University Health Network (CA) 2024-05-22 EP claimed
CN-117980004-A Porphyrin nanovesicles with fatty acid conjugates 大学健康网络 2024-05-03 CN claimed
WO-2023283732-A1 PORPHYRIN NANOVESICLE WITH FATTY ACID CONJUGATE UNIVERSITY HEALTH NETWORK (CA) 2023-01-19 WO claimed
WO-2020125119-A1 AQUEOUS CAPSULES AND PREPARATION METHOD THEREFOR 云南巴菰生物科技有限公司 2020-06-25 WO claimed
CN-106474474-B Photo-thermal nano particle based on peptide and photosensitizer, preparation method and application thereof 中国科学院过程工程研究所 2020-02-14 CN claimed
US-20190307893-A1 NANOVESICLES WITH PORPHYRIN-LIPID CONJUGATE CORE UNIVERSITY HEALTH NETWORK (CA) 2019-10-10 US claimed
WO-2019136118-A2 CELL-ASSOCIATING IMMUNOLOGIC ADJUVANTS FOR TREATMENT ENHANCEMENT ACADEMIA SINICA (TW) 2019-07-11 WO claimed
EP-2717857-B1 METHOD FOR THE SYNTHESIS OF PORPHYRIN-PHOSPHOLIPID CONJUGATES UNIV HEALTH NETWORK UHN (CA) 2018-07-11 EP claimed
EP-3310387-A1 SPECIFIC PHOTOIMMUNO-THERANOSTICS FOR DETECTION AND ELIMINATION OF SKIN CANCER CELLS Fraunhofer Gesellschaft zur Förderung der Angewand (DE) 2018-04-25 EP claimed
EP-2488206-B1 PORPHYRIN NANOVESICLES UNIV HEALTH NETWORK UHN (CA) 2018-03-21 EP claimed
EP-1993356-A2 ORAL DELIVERY OF THERAPEUTIC AGENTS USING TIGHT JUNCTION AGONISTS Alba Therapeutics Corp. (US) 2008-11-26 EP claimed
EP-1933875-A2 CONJUGATES OF PHOTOSENSITISERS AND ANTIBODIES Photobiotics Limited (GB) 2008-06-25 EP claimed
WO-2007095091-A2 ORAL DELIVERY OF THERAPEUTIC AGENTS USING TIGHT JUNCTION AGONISTS ALBA THERAPEUTICS CORPORATION (US) 2007-08-23 WO claimed
WO-2007042775-A2 CONJUGATES OF PHOTOSENSITISERS AND ANTIBODIES PHOTOBIOTICS LIMITED (GB) 2007-04-19 WO claimed
WO-2006133271-A2 COMPOSITIONS AND METHODS RELATING TO TARGET-SPECIFIC PHOTODYNAMIC THERAPY THE GENERAL HOSPITAL CORPORATION (US) 2006-12-14 WO claimed
US-20060013454-A1 Systems for identifying, displaying, marking, and treating suspect regions of tissue MEDISPECTRA, INC. (US) 2006-01-19 US claimed
US-20050154277-A1 Apparatus and methods of using built-in micro-spectroscopy micro-biosensors and specimen collection system for a wireless capsule in a biological body in vivo TANG JING (US) 2005-07-14 US claimed
US-20050148842-A1 Positioning devices and methods for in vivo wireless imaging capsules WANG LEMING (US) 2005-07-07 US claimed
WO-2004032803-A1 STENT WITH RING ARCHITECTURE AND AXIALLY DISPLACED CONNECTOR SEGMENTS COOK INCORPORATED (US) 2004-04-22 WO claimed
WO-1997040888-A1 THERAPY APPARATUS AND METHOD GLAXO GROUP LIMITED (GB) 1997-11-06 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190307893-A1 NANOVESICLES WITH PORPHYRIN-LIPID CONJUGATE CORE PHOSPHO1, PCYT1A, CLTB HSD17B10 629/4885TSHR 1358/4885HPGD 3115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.